Probiotics for Anti-Aging: The Inflammaging Trial and What's Behind It

Inflammaging: A Real, Measurable Aging Target

"Inflammaging" describes the chronic, low-grade systemic inflammation that tends to rise with age even without acute illness, and it's linked to a wide range of age-related conditions. Because gut bacteria influence circulating inflammatory markers through the intestinal barrier and immune signaling, probiotics are a mechanistically reasonable candidate for addressing inflammaging specifically -- a more concrete target than "anti-aging" in the abstract. A randomized trial has now tested this directly in the population where it matters most: older adults with measurable baseline inflammation.

The Trial: A Specific Strain in Older Adults With Inflammation

A randomized, double-blind, placebo-controlled trial published in Probiotics and Antimicrobial Proteins enrolled 66 adults over age 70 (mean age 73.2) who had systemic low-grade inflammation at baseline (CRP 2–10 mg/L), and gave them either placebo, the strain Lactiplantibacillus plantarum HEAL9 (1×10¹&sup0; CFU/day), or that strain plus lyophilized berries, for four weeks after a two-week washout. The honest result: the HEAL9 group showed a significant decrease in fecal calprotectin (a gut inflammation marker) compared to placebo, and only a non-significant trend toward lower serum CRP -- the more commonly cited systemic inflammation marker did not reach statistical significance. There was also a trend toward improved cognitive function across probiotic groups. Notably, adding berries to the same strain showed no additional inflammation benefit, suggesting the combination didn't work as hoped. This is a real, well-designed human RCT directly on an aging-relevant outcome -- but it's a modest, mixed result, not a clean across-the-board win.

The Mechanism: A 2026 Mouse Study on a Different Strain

A 2026 study in Nature Aging examined a different probiotic species, Bifidobacterium pseudocatenulatum (strain NCU-08), in aging mice (the SAMP8 senescence-accelerated model), identifying a specific bacterial metabolite (L-tryptophan-derived) that activated longevity-associated signaling pathways (AMPK/Sirt1) and reduced inflammaging markers while restoring intestinal barrier integrity. This is a compelling mechanistic story for how a gut bacterium could plausibly influence aging biology -- but it's a different bacterial strain than the one used in the human trial above, tested only in mice, so it explains a plausible pathway rather than confirming it works the same way in people.

What This Does and Doesn't Show

The honest summary: inflammaging is a real, biologically grounded target, and one specific probiotic strain has now been tested against it in a proper human RCT in older adults -- with a genuinely mixed result (a real reduction in gut-level inflammation, but not in the systemic CRP marker most people associate with "inflammation"). A separate, mechanistically rich mouse study using a different strain shows a plausible biological pathway for how gut bacteria could influence aging signaling more broadly. Neither result supports a strong claim that probiotic supplementation will measurably slow aging in humans -- the specific strain matters, and even the best human evidence so far shows a partial effect on a narrower marker.

Practical Takeaway

• The trial with a positive result used a specific studied strain (Lactiplantibacillus plantarum HEAL9) at a specific dose (1×10¹&sup0; CFU/day) -- results with other strains or lower CFU counts aren't established by this trial
• Don't expect a measurable drop in standard CRP blood tests based on current evidence -- the significant result was on a gut-specific marker (fecal calprotectin), not systemic CRP
• The mouse mechanism study used a different bacterial species entirely -- it's supporting biological plausibility, not a human-equivalent result
• Probiotics remain generally well tolerated in healthy older adults in the trials reviewed here